The role of 18FDG PET/CT for the initial staging and therapy in primary breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 13, 2009, Pages 2526-2531

  Inokuchi, Masafumi ^a,b   Furukawa, Hiroyuki ^a,b   Kayahara, Masato ^a   Ohta, Tetsuo ^a   Kawashima, Hiroko ^b   Taki, Junichi ^a   Kinuya, Seigo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Axillary staging; Breast cancer; FDG PET CT; Neoadjuvant chemotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMOTHERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MICROMETASTASIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIMARY TUMOR; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84983520536     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Fletcher JW, Djulbegovic B, Soares HP, et al: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480-508, 2008. (Pubitemid 351355215)
2. Hayashi M, Murakami K, Oyama T, et al: PET/CT supports breast cancer diagnosis and treatment. Breast Cancer 15:224-230, 2008.
3. Adler LP, Crowe JP, AI-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with [18-F] 2-deoxy-fluoro-D-glucose PET. Radiology 187:743-750, 1993. (Pubitemid 23155705)
4. Oshida M, Uno K, Suzuki M, et al: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-fluoro [18-F]-D-glucose. Cancer 82:2227-2234, 1998. (Pubitemid 28240830)
5. Rosen EL, Eubank WB and Mankoff DA: FDG PET, PET/CT, and breast cancer imaging. Radiographics 27:215-229, 2007.
6. Lim HS. Yoon W, Chung TW, et al: FDG PET/CT for the detection and evaluation of breast diseases: Usefulness and limitations. Radiographics 27(Suppl 1): S197-213, 2007.
7. Wahl RL, zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemotherapy using positron emission tomography. J Clin Oncol 11:2101-2111, 1993. (Pubitemid 23332245)
8. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [(18F)] fluoro-deoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000. (Pubitemid 30220547)
9. Tilling R, Linke R, Untch M, et al: 18F-FDG PET and 99mTc-sestamibi scinti-mammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study. Eur J Nucl Med 28:711-720, 2001.
10. Kumar A, Kumar R, Seenu V, et al: The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 19:1347-1357, 2009.
11. Duch J, Fuster D, Munoz M, et al: 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 36(10):1551-1557, 2009.
12. Kim SJ, Kim SK, Lee ES, et al: Predictive value of [18F] FDG-PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15:1352-1357, 2004. (Pubitemid 39295023)
13. Lavoisier R, Caber AE and Filament JE: Positron emission tomography (PET) and breast cancer in clinical practice. Eur Radiol 69:50-58, 2009.